301015 百洋医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)13.90226.41022.72223.23619.815
总资产报酬率 ROA (%)6.49512.70810.5189.8017.340
投入资产回报率 ROIC (%)7.69115.46912.90112.4029.566

边际利润分析
销售毛利率 (%)31.52629.97527.76125.12725.059
营业利润率 (%)13.27111.7418.9797.9636.259
息税前利润/营业总收入 (%)13.96812.2879.5478.8887.249
净利润/营业总收入 (%)10.1838.4606.5235.8854.715

收益指标分析
经营活动净收益/利润总额(%)99.30298.658101.35497.099101.858
价值变动净收益/利润总额(%)4.2644.994-1.3271.7292.384
营业外收支净额/利润总额(%)-0.541-1.663-0.8540.6960.778

偿债能力分析
流动比率 (X)1.9872.4491.6351.7041.418
速动比率 (X)1.7502.0721.3861.4441.174
资产负债率 (%)56.95150.13254.68852.7670.625
带息债务/全部投入资本 (%)47.33836.28640.60441.42051.879
股东权益/带息债务 (%)106.544168.566137.491139.61592.448
股东权益/负债合计 (%)76.424100.45883.67188.82458.826
利息保障倍数 (X)18.18716.64714.81710.2187.708

营运能力分析
应收账款周转天数 (天)102.21197.58593.13487.17183.807
存货周转天数 (天)47.46845.35742.27042.07744.836